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Background: Although thrombocytopenia, anasarca, fever, reticulin fibrosis, and 
organomegaly (TAFRO) syndrome was first described as a variant of idiopathic 
multicentric Castleman disease, patients with TAFRO syndrome have more aggressive 
clinical features. Because these patients may present with fever of unknown origin, 
general physicians need to recognize its characteristic laboratory data and clinical 
features during hospitalization.    
Aims: Herein, we described the features, symptoms, and characteristics of TAFRO 
syndrome and compared them to those of idiopathic Castleman disease. 
Methods: This was a retrospective study of patients with histopathologically confirmed 
TAFRO syndrome and idiopathic multicentric Castleman disease who were diagnosed 
and managed between April 2012 and June 2018 in a Japanese university hospital 
General Medicine Department. 
Results: We found that the hospitalizations were significantly longer among patients 
with TAFRO syndrome compared to those with idiopathic Castleman disease (median: 
87 days; range: 34-236 days vs. median: 30 days; range: 13-59 days; p < 0.01). Patients 
with TAFRO syndrome were more likely to present with fever, abdominal pain, and 
elevated inflammatory markers and be misdiagnosed with an infectious disease during 
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the first hospital visit. Approximately 40% of patients with TAFRO syndrome had no 
radiographically enlarged lymph nodes. 
Conclusions: TAFRO syndrome may present like an infectious disease with an 
aggressive clinical course. Our study highlights the importance of placing significance 
on chief complaints and laboratory data. Physicians need to recognize the clinical and 
laboratory features of this disease to avoid missing this potentially fatal disorder.  
 
Keywords 















 Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly, 
(TAFRO) syndrome is a new clinical entity that was first described in 2010 as a variant 
of idiopathic multicentric Castleman disease (iMCD)1. It is a systemic inflammatory 
disorder characterized by thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis 
(R), and organomegaly (O) with aggressive clinical features as previously described1-5. 
Castleman disease (CD) is a rare and heterogenous lymphoproliferative disorder that was 
first described over 60 years ago6. It is divided into two subtypes; localized or unicentric 
Castleman disease, and multicentric Castleman disease (MCD). MCD is characterized by 
organomegaly, elevated serum pro-inflammatory cytokines such as interleukin 6 (IL-6), 
and polyclonal hypergammaglobulinaemia7. Pathologically, MCD is classified into one 
of the following four categories; hyaline vascular, plasma cell, mixed, or plasma-blastic 
type, thus making the disease heterogenous8. Previously, MCD was considered to occur 
mainly in association with human herpes virus 8 (HHV-8) infection in 
immunocompromised patients9. However, it was recently reported that HIV-negative and 
HHV-8 negative MCD were more prevalent, accounting for approximately 50% of cases 
of MCD in the United States7. iMCD was thus further defined by HIV and HHV-8 
negative MCD subtypes. Reports of TAFRO syndrome have been described recently in 
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Western countries among Caucasian populations10-13. Although the clinical characteristics 
are similar in these two disorders, TAFRO syndrome has been described as a clinical 
entity distinct from iMCD because TAFRO syndrome is usually associated with 
hypogammaglobulinemia, which is in stark contrast to iMCD, and poor treatment 
response14. However, the boundaries between TAFRO syndrome and other iMCD have 
not been well defined. These facts signify the importance of recognizing the clinical 
characteristics of TAFRO syndrome and iMCD given these disorders may be more 
prevalent and different than previously thought.  
Although the clinicopathological characteristics of TAFRO syndrome have been 
reported previously15, 16, no studies have clearly described its clinical presentation 
according to the chief complaint, symptoms, and hospital-related characteristics. 
Although TAFRO syndrome has been gaining recognition recently, not all generalists are 
aware of the clinical characteristics and presentations of the disease. Since patients with 
TAFRO syndrome present with various complaints and symptoms including prolonged 
fever17-20, patients may be referred to or admitted to internal medicine services for further 
investigation. Thus, it is important for internists to recognize the clinical characteristics 
of TAFRO syndrome given that the disease may be fatal.  
The purpose of this study is to help define the boundaries between TAFRO 
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syndrome and other iMCD, while revealing the laboratory and clinical features of TAFRO 
syndrome and compare them to those of iMCD, with a focus on the patients’ history of 
present illness, symptoms, and clinical characteristics during hospitalization. 
 
METHODS 
Design and study population 
This was a retrospective observational study. We included 15 patients who were 
admitted and diagnosed with TAFRO syndrome or HIV-negative and HHV-8-negative 
iMCD from April 2012 to June 2018 in the General Medicine Department of Okayama 
University Hospital, Okayama, Japan. Okayama University Hospital has 813 beds. In 
this study, all the patients were of Japanese descent. Of the 15 included patients, 8 were 
diagnosed with TAFRO syndrome and 7 were diagnosed with iMCD. The patients had 
lymph node biopsies for diagnosis. All patients were treated in our department in 
conjunction with a team of haematologists. The data were reviewed retrospectively by 
the physicians after informed consent was obtained from the patients. The study 
protocol was approved by the institutional review board of Okayama University 





The patients’ data were reviewed retrospectively to determine whether they were 
compatible with the proposed diagnostic criteria for TAFRO syndrome and iMCD21-23. 
Patients with TAFRO syndrome were those who met two sets of proposed diagnostic 
criteria21, 23. The diagnostic criteria of TAFRO syndrome proposed by Iwaki et al. 
includes (1) histopathological lymph node appearance consistent with TAFRO 
syndrome, e.g., atrophic germinal centres with enlarged endothelial cell nuclei, (2) at 
least three of the five primary diagnostic criteria including thrombocytopenia, anasarca, 
fever, reticulin fibrosis, and organomegaly, in the presence of small volume 
lymphadenopathy without hypergammaglobulinemia, (3) at least one of the following 
minor criteria: hyper- or normoplasia of megakaryocytes in the bone marrow, or an 
elevated alkaline phosphatase level without marked elevation of serum transaminases. 
Thrombocytopenia was defined as a platelet count < 100,000 at least once prior to the 
diagnosis. Anasarca was defined as the existence of a pleural effusion or ascites on 
computed tomography (CT). Fever was defined as a body temperature ≧ 38.0℃ at 
least once prior to the diagnosis. Reticulin fibrosis was identified on bone marrow 
biopsy. Organomegaly included hepatomegaly (vertical liver span ≧ 15cm) and 
splenomegaly (vertical span ≧ 10cm). The differential diagnosis included infection, 
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POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin 
pigmentation) syndrome, autoimmune diseases such as systemic lupus erythematosus, 
and malignancy, which were ruled out in all patients. The baseline data prior to any 
treatment were used in the analysis. 
 
Statistical analysis 
We used Wilcoxon and Kruskal-Wallis tests to investigate the differences between 
the continuous data of the two groups. The Fisher’s exact test was used to detect 
significant differences in the categorical data between the two groups. The threshold for 
significance was P < 0.05. All statistical analyses were conducted using JMP Version 13 




   The demographics and laboratory findings are summarized in Table 1. 
Representative findings with regard to laboratory data are shown in Figures 1 and 2. The 
median ages of the patients were 43.5 and 48.0 in the TAFRO and the iMCD groups, 
respectively, and the difference was not significant. In the TAFRO group, 5 (62.5%) 
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patients were men. White-blood cell counts, D-dimer, blood urea nitrogen (BUN), 
creatinine, alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT) levels 
were more elevated in the TAFRO group than the iMCD group, but there were no 
statistically significant differences. Of note, the neutrophil fraction was significantly 
elevated in the TAFRO group (p < 0.01). The total protein and albumin levels were 
significantly decreased in the TAFRO group with medians of 47 g/L (range: 38-61 g/L) 
and 19 g/L (11-23 g/L), respectively (p < 0.01), whereas total protein levels were 
markedly elevated in the iMCD group (median: 96 g/L, range: 72-115 g/L). The patients 
in the TAFRO group had significantly elevated total bilirubin levels with a maximum 
value of 151.0 μmol/L (median: 17.6 μmol/L, range: 5.5-151.0 μmol/L) with a 
significant decrease in cholinesterase level (median: 58 U/L, range: 32-80 U/L) (p < 0.01). 
Inflammatory markers including serum ferritin, C-reactive protein (CRP), and 
procalcitonin (PCT) levels were markedly elevated in the TAFRO group (p < 0.01). The 
median PCT level was elevated up to 6 times that of the level iMCD group (the median 
4.76 ng/mL vs. 0.093 ng/mL respectively). No significant differences were observed in 
the serum soluble interleukin-2 receptor (sIL-2R), IL-6, and vascular endothelial growth 
factor (VEGF) levels. Correlations between CRP and PCT or ALP are shown in Figure 2. 
There was no correlation between CRP and PCT in both groups. Among the patients with 
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TAFRO syndrome, there was a moderate correlation between CRP and ALP levels, 
although no statistical significance was observed.    
 
Clinical characteristics 
   Clinical findings including the chief complaints, symptoms, and other disease-
specific characteristics identified during the hospitalizations are described in Table 2.  
Difference in the lengths of hospitalization between the groups is shown on the 
graph in Figure 1. The median duration until the diagnosis was made was 10 days (range: 
5-47 days) in the TAFRO group and 13 days (range: 11-62 days) in the iMCD group, and 
the difference was not significant. However, the length of hospitalization was 
significantly longer in the TAFRO group (median: 87 days, range: 34-236 days) compared 
with the iMCD group (median: 30 days, range: 13-59 days) (p < 0.01). The patients with 
TAFRO syndrome more commonly presented with fever, abdominal pain, or cough. 
Interestingly, none of the patients were correctly diagnosed with TAFRO syndrome or 
iMCD initially. In the TAFRO group, 6 patients (75%) were initially diagnosed and 
managed as if they had an infectious disease. Other patients were first diagnosed with 
autoimmune diseases or heart failure. In contrast, the patients with iMCD were first 
diagnosed with a variety of disorders including infection, autoimmune disease, 
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malignancy, IgG4-related disease (IgG4-RD), and small bowel obstruction. The reasons 
for hospitalization in patients with TAFRO syndrome were mostly fever of unknown 
origin or abdominal pain, whereas the patients with iMCD had various reasons including 
pleural effusion and generalized fatigue. Regarding the symptoms, almost all patients in 
the TAFRO group had fever for the duration of their treatments, whereas only 2 patients 
(28.6%) in the iMCD group exhibited fever in our study population (p < 0.05). The fever 
type was more likely to be remitting and relapsing in the TAFRO group compared with 
the iMCD group, although statistical significance was not observed. In contrast, all the 
patients with iMCD presented with intermittent fevers. In our study population, only a 
few patients in iMCD group had night sweats or weight loss. None of the patients in the 
TAFRO group had these symptoms. Interestingly, 3 patients (37.5%) in the TAFRO group 
did not have lymphadenopathy. Anasarca, defined by the presence of pleural effusion 
and/or ascites, or lower extremity oedema, was significantly more common in the TAFRO 
group (p < 0.01).  
As for the treatment regimens, the first-line treatment for patients with TAFRO 
syndrome was more likely to be methylprednisolone pulse therapy (6/8; 75%). The iMCD 
patients tended to receive lower-dose prednisolone therapy defined by doses equal to or 
less than 0.5mg/kg (5/7, 71.4%). The choices for second-line therapy were mainly 
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tocilizumab (anti-IL-6 monoclonal antibody), rituximab (anti-CD20 monoclonal 
antibody), or cyclosporine (calcineurin inhibitor) in the TAFRO group. One patient in the 
group underwent bortezomib therapy as a second-line therapy. All of the patients with 
TAFRO syndrome required the second-line treatment. In contrast, 2 patients (28.6%) in 
the iMCD group had no second-line treatment, suggesting that patients with iMCD 
responded to corticosteroids better than those with TAFRO syndrome. The third-line 
treatment regimen included mainly tocilizumab or rituximab in both groups. One patient 
in each group died during the treatment periods. 
 
Factors affecting the length of hospitalization 
The results of the linear regression analysis showing the correlation between the 
length of hospitalization and cholinesterase level is shown in Figure 2. There was a 
significant negative correlation between the length of hospitalization and the serum 
cholinesterase level in patients with TAFRO syndrome. There was also a weak correlation 
between the length of hospitalization and the serum CRP level in patients with TAFRO 





 Our study is the first retrospective, exploratory analysis to examine the clinical 
and laboratory differences between TAFRO syndrome and iMCD among patients in the 
general internal medicine department. Compared to previous studies21, 24, we focused on 
clarifying not only the laboratory values, but also the clinical factors including the patients’ 
first complaints, diagnostic information, and detailed data acquired during the 
hospitalization. Although the study was conducted in the Japanese population and a 
caution to geographical variation should be made when interpreting the data, our results 
showed that there was a significant difference in the laboratory data including WBC 
differentials, platelet counts, immunoglobulins, and inflammatory markers such as CRP 
and PCT, between the patients with TAFRO syndrome and those with iMCD. As for 
clinical factors, patients with TAFRO syndrome had significantly longer lengths of 
hospitalization, which may be a surrogate marker of disease severity. Symptomatically, 
fever and anasarca were more common in patients with TAFRO syndrome. Patients with 
TAFRO syndrome patients tended to receive more aggressive treatment regimens, 
including methylprednisolone pulse therapy. We also found that lower cholinesterase and 
IgG4 levels at baseline were significantly correlated with longer lengths of hospitalization 
in the patients with TAFRO syndrome, which may be useful for comprehensive planning 




   Previous studies have presented a different perspective for patients with TAFRO 
syndrome, questioning whether it is a subtype of iMCD or not. A retrospective study 
suggested that platelet counts, serum Alb, and immunoglobulin levels were significantly 
decreased, while CRP and ALP were significantly elevated in patients with TAFRO 
syndrome compared to those with iMCD21. These tendencies were also true in our data. 
Our results also showed that the proportion of neutrophils was significantly increased in 
patients with TAFRO syndrome. In our study population, 50% of patients with TAFRO 
syndrome complained of abdominal pain at the first encounter and their serum PCT was 
also significantly elevated. These facts raise a concern that TAFRO syndrome can easily 
lead to clinical presentations that mimic abdominal infectious diseases due to 
hepatobiliary inflammation. Adequate attention should be paid to rule out a known 
infectious aetiology as noted by the disease definition.  
    
A previous retrospective study from Thailand reported on the clinical 
presentations of patients with TAFRO syndrome and iMCD25. Their findings showed that 
all the patients with TAFRO syndrome presented with lymphadenopathy. Contrary to that 
previous report, only about 60% of the patients with TAFRO syndrome in this study 
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exhibited lymphadenopathy. Because TAFRO syndrome was first characterized by small 
volume lymphadenopathy, less than 1.5cm in diameter23, the patients may not have shown 
obvious lymph node enlargements on the CT scans. Our findings are supported by a 
previous study that investigated the CT findings of patients with TAFRO syndrome, 
which found that approximately 20% of the patients did not have lymphadenopathy16. 
This point is important for internists to recognize, because these patients need to be 
referred for lymph node biopsy even in the absence of apparent lymphadenopathy. 
Internists should recognize the unique features of lymphadenopathy and lymph node size 
in patients with TAFRO syndrome, and the fact that lymph node biopsy is essential for 
making the diagnosis of TAFRO syndrome.     
 
This study showed that the length of hospitalization was significantly longer in 
patients with TAFRO syndrome. Although there is the premise that the average length of 
hospitalization in a Japanese acute care bed is 16.3 days26, which is considerably long 
compared with that in other countries, the length of hospitalization for patient with 
TAFRO syndrome is still long. This may reflect the fact that the patients with TAFRO 
syndrome had more aggressive clinical courses, as shown by the differences in the 
treatment regimens. Thus, length of hospitalization may be a surrogate marker of disease 
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severity. Patients with TAFRO syndrome were more likely to have corticosteroid pulse 
therapy as the first-line therapy, and about 80% of patients received third-line treatments 
as well. In addition, there was a weak positive correlation between serum CRP and the 
length of hospitalization. This suggests that cholinergic activity may modulate the 
systemic inflammatory response27, and reduced serum cholinesterase levels could predict 
mortality after sepsis28. Our findings also suggest that IgG4 is produced to attenuate 
systemic inflammation29. Thus, decreased cholinesterase and IgG4 levels may reflect the 
extent of hyper-inflammatory status and a dysregulation of the immunomodulatory 
process in patients with TAFRO syndrome. Further pathophysiological investigations are 
required to elucidate the mechanism of action of these molecules. 
    
   Our study has a few limitations that needed to be considered when reviewing the 
results. First, our study was conducted at a single Japanese university hospital, which 
reduces the generalizability of the results to patients of other ethnicities. Second, because 
both TAFRO syndrome and iMCD are rare diseases, only 15 patients were included in 





   We performed a retrospective analysis to elaborate the clinical and laboratory 
characteristics of patients with TAFRO syndrome compared to patients with iMCD. There 
was a significant difference in the laboratory values including platelet count, ALP, 
immunoglobulin, and inflammatory markers. Patients with TAFRO syndrome were more 
likely to initially present with abdominal pain and be misdiagnosed with an infectious 
disease. Internists should recognize these characteristics of TAFRO syndrome so as not 
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Figure 1. Characteristic laboratory data comparison of the patients with TAFRO 
syndrome and idiopathic multicentric Castleman Disease 
Difference between C-reactive protein (CRP), procalcitonin (PCT), neutrophil 
fraction, cholinesterase (ChE), immunoglobulin G (IgG), immunoglobulin G4 (IgG4), 
and albumin (Alb) levels and length of hospitalization (LOS) between the patients with 
TAFRO syndrome and iMCD are shown. The mean values and ±SEM are shown in the 
data. * p < 0.05, ** p < 0.01, ***p < 0.001.  
TAFRO: thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly 
 
Figure 2. Correlation between clinical and laboratory factors  
   A linear regression analysis is presented to elaborate on the correlations between 
C-reactive protein (CRP) and procalcitonin (PCT), alkaline phosphatase (ALP), and CRP 
levels; length of hospitalization (LOS) and cholinesterase (ChE) level; and LOS and CRP. 
The correlations are compared between the TAFRO and the iMCD groups. Blue and red 
marked areas indicate trust regions. * p < 0.05, ** p < 0.01, ***p < 0.001. 
 
 
